Oxford Immunotec Global PLC (OXFD) reported quarterly earnings results on Tuesday, Aug-2-2016. The company said it had a profit of $-0.29 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.32. The company posted revenue of $19.20 million in the period, compared to analysts expectations of $18.12 million. The company’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.33 EPS.
Oxford Immunotec Global PLC closed down -0.28 points or -3.37% at $8.04 with 83,181 shares getting traded on Friday. Post opening the session at $8.04, the shares hit an intraday low of $7.83 and an intraday high of $8.33 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Nov 20, 2015, Richard A Sandberg (director) sold 5,000 shares at $13.49 per share price.
Oxford Immunotec Global PLC is a global commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis prognosis and monitoring of patients with immune-regulated conditions. The Company’s development activities are focused on four areas: chronic infections transplantation autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for Tuberculosis. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus. The T-SPOT.PRT test assesses T cell responses to foreign tissue. T-SPOT.ICA assay measures the competence of T cells. The Company has three products targeting the autoimmune and inflammatory disease area: SpiroFind assay GoutiFind and Stratokine.